NEW YORK ─ SomaLogic on Friday initiated full-year 2022 revenue guidance, saying it expects approximately $105 million to $110 million.
The firm's CEO Roy Smythe said in a statement that it is growing the size of its commercial team and diversifying its product offerings at a time of "rapidly increasing demand for proteomics solutions and services."
At the 40th Annual JP Morgan Healthcare Conference in January, Boulder, Colorado-based SomaLogic said it expects 2021 revenues to exceed $79 million.
The developer of artificial intelligence-based proteomics technology said it will announce final fourth quarter and full-year 2021 results in March.